By Key Points
Medtronic (NYSE: MDT), one of the world’s largest medical device makers, was once considered a stable blue chip stock. But over the past five years, it has declined by more than 30% due to supply chain constraints, higher costs, quality control issues, and competitive pressure. However, Medtronic’s stock is worth buying again for four simple reasons.
1. It’s growing again
In fiscal 2026 (which ended this April), Medtronic’s revenue grew 8.4% (and 5.8% organically) to $36.4 billion, marking its strongest top-line growth in ten years.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
That acceleration was driven by 9.3% organic growth in its cardiovascular business, which accounted for more than 38% of its enterprise revenue. All of its other segments (neuroscience, medical surgical, and diabetes) also grew organically.
Medtronic expects its organic revenue to rise 7.25%-7.75% in fiscal 2027, representing another multi-year high and easily exceeding its historical average of around 5%. Once again, that growth will be led by its rising sales of cardiovascular devices. From fiscal 2026 to fiscal 2029, analysts expect its reported revenue to grow at a 5% CAGR.
2. Its cash flow is growing
Medtronic has been restructuring its business to free up more cash to fund its dividends while expanding its higher-growth cardiovascular and neuroscience portfolios. Over the past year, it spun off its diabetes unit as MiniMed (NASDAQ: MMED), overhauled its cardiovascular business, pruned its workforce, and announced the closure of its Santa Rosa campus.
As a result, its free cash flow (FCF) grew 4.6% to $5.43 billion in fiscal 2026. It spent only $3.64 billion of that total on dividends, leaving ample room for future hikes.
3. It’s a future Dividend King
Medtronic pays a forward yield of 3.1%. It’s raised its payout for 49 consecutive years, putting it on track to become a Dividend King if it crosses the 50-year mark next year.
4. It’s still undervalued
From fiscal 2026 to fiscal 2029, analysts expect Medtronic’s EPS to grow at a 14% CAGR. But at $92, its stock trades at just 18 times next year’s earnings. That makes it much cheaper than many of its industry peers and the S&P 500 — which trades at 21 times forward earnings.
Medtronic isn’t an exciting stock, but it’s overcome most of its prior challenges and should grow again as it expands its cardiovascular and neuroscience businesses. Only a handful of companies can match Medtronic’s scale and diversification, so it’s still a reliable long-term play for investors who want an income-generating stock with a wide moat.
Should you buy stock in Medtronic right now?
Before you buy stock in Medtronic, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medtronic wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $446,157!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,377,357!*
Now, it’s worth noting Stock Advisor’s total average return is 984% — a market-crushing outperformance compared to 212% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 3, 2026.
Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Medtronic. The Motley Fool has a disclosure policy.
